Drugs acting on the immune system

Side Effects of Drugs Annual

Volumn 23, Issue , 2000, Pages 391-417

  Vial, Thierry ^a   Descotes, Jacques ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35649020876     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(00)80043-4     Document Type: Article

References (172)

1. Cacopardo B Benanti F Brancati G Romano F Nunnari A Leucocyte interferon- α retreatment for chronic hepatitis C patients previously intolerant to other interferons J Viral Hepatitis 5 1998 333 339
2. Anonymous Interferon- α -2b and ribavirin combination therapy-indications extended: previously untreated hepatitis C patients WHO News-letter 1/2 1999 9
3. Colivicchi F Magnanimi S Sebastiani F Silvestri R Magnanimi R Incidence of electrocardiographic abnormalities during treatment with human leukocyte interferon-alfa in patients with chronic hepatitis C but without preexisting cardiovascular disease Curr Ther Res Clin Exp 59 1998 692 696
4. Parrens E Chevalier JM Rougier M Douard H Labbé L Quiniou G Broustet A Broustet J0P Apparition d'un bloc auriculo-ventriculaire du troisième degré sous interféron α : à propos d'un cas Arch Mal Coeur Vaiss 92 1999 53 56
5. Cid MC Hernandez-Rodriguez J Robert J Del Rio A Casademont J Coll-Vinent B Grau JM Kleinman HK Urbano-Marquez A Cardellach F Interferon- α may exacerbate cryoglobulinemia related, ischemic manifestations Arthritis Rheum 42 1999 1051 1055
6. Bini EJ Weinshel EH Severe exacerbation of asthma: a new side effect of interferon- α in patients with asthma and chronic hepatitis C Mayo Clin Proc 74 1999 367 370
7. Wörle H Maass E Köhler B Treuner J Interferon alpha-2a therapy in haemangiomas of infancy: spastic diplegia as a severe complication Eur J Pediatr 158 1999 344
8. Enjolras O Neurotoxicity of interferon- α in children treated for hemangiomas J Am Acad Dermatol 39 1998 1037 1038
9. Grether JK Nelson KB Dambrosia JM Phillips TM Interferons and cerebral palsy J Pediatr 134 1999 324 332
10. Brouwers PJ Bosker RJI Schaafsma M Wilts G Neef C Photosensitive seizures associated with interferon alfa-2a Ann Pharmacother 33 1999 113 114
11. Horikawa N Yamazaki T Sagawa M Nagata T A case of akathisia during interferon- α therapy for chronic hepatitis type C Gen Hsop Psychiatry 21 1999 134 140
12. Capuron L Ravaud A Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state New Engl J Med 340 1999 1370
13. Monji A Yoshida I Tashiro KI Hayashi Y Tashiro N A case of persistent manic depressive illness induced by interferon-alfa in the treatment of chronic hepatitis C Psychosomatics 39 1998 562 564
14. Valentine AD Managing the neuropsychiatric adverse effects of interferon treatment BioDrugs 11 1999 229 237
15. Fortis A Christopoulos C Chrysadakou E Anevlavis E De Quervain's thyroiditis associated with interferon- α -2b therapy for non-Hodgkin's lymphoma Clin Drug Invest 16 1998 473 475
16. Ghilardi G Gonvers JJ So A Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection Br J Rheumatol 37 1998 1349 1351
17. Schmitt K Hompesch BC Oeland K Von Straehr WG Thürmann PA Autoimmune thyroiditis, and myelosuppression following treatment with interferon- α for hepatitis C Int J Clin Pharmacol Ther 37 1999 165 167
18. Fernandez-Soto L Gonzalez A Escobar-Jimenez F Vazquez R Ocete E Olea N Salmeron J Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing, interferon therapy Arch Intern Med 158 1998 1445 1448
19. Kakizaki S Takagi H Murakami M Takayama H Mori M HLA antigens in patients with interferon- α -induced autoimmune thyroid disorders in chronic hepatitis C J Hepatol 30 1999 794 800
20. Minelli R Braverman LE Valli MA Schianchi C Pedrazzoni M Fiaccadori F Salvi M Magotti MG Roti E Recombinant interferon α (rIFN- α ) does not potentiate the effect of iodine excess on the development of thyroid abnormalities in patient with HCV chronic active hepatitis Clin Endocrinol 50 1999 95 100
21. Calvino J Romero R Suarez-Penaranda JM Arcocha V Lens XM Mardaras J Novoa D Sanchez-Guisande D Secondary hyperpara-thyroidism exacerbation: a rare side-effect of interferon-alpha? Clin Nephrol 51 1999 248 251
22. Elisaf M Tsianos EV Severe hypertriglyceridaemia in a non-diabetic patient, after α -interferon Eur J Gastroenterol Hepatol 11 1999 463
23. Junghans V RĄnger TM Hypertriglyceridaemia following adjuvant interferon- α treatment in two patients with malignant melanoma Br J Dermatol 140 1999 168 192
24. Fernandez-Miranda C Castellano G Guijarro C Fernandez I Schöebel N Larumbe S Gomez-Izquierdo T Del Palacio A Lipoprotein changes in patients with chronic hepatitis C treated with interferon- α Am J Gastroenterol 93 1998 1901 1904
25. Peck-Radosavljevic M Wichlas M Pidlich J Sims P Meng G Zacherl J Garg S Datz C Gangl A Ferenci P Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C Hepatology 28 1998 1424 1429
26. Martin TG Shuman MA Interferon-induced thrombocytopenia: is it time for thrombopoietin? Hepatology 28 1998 1430 1432
27. Toccaceli F Rosati S Scuderi M Iacomi F Picconi R Laghi V Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment Hepato-Gastroenterology 45 1998 1748 1752
28. Rachmani R Avigdor A Youkla M Raanani P Zilber M Ravid M Ben Bassat I Thrombotic thrombocytopenic purpura complicating chronic myelogenous leukemia treated with interferon- α . A report of two successfully treated patients Acta Haematol 100 1998 204 206
29. Zylberberg H Fontaine H Thépot V Nalpas B Bréchot C Pol S Triggering of acute alcohol hepatitis by α -interferon therapy J Hepatol 30 1999 722 725
30. Garrido Palma G Sanchez Cuenca JM Olaso V Pina R Urquijo JJ Lopez Viedma B Bustamante M Berenguer M Berenguer J Response to treatment with interferon-alfa in patients with chronic hepatitis C and high titers of-M2,-M4 and-M8 antimitochondrial antibodies Rev Esp Enferm Dig 91 1999 175 181
31. Shah M Jenis EH Mookerjee BK Schriber JR Baer MR Herzig GP Wetzler M Interferon- α -associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy Cancer 83 1998 1938 1946
32. Eberlein-König B Hein R Abeck D Engst R Ring J Cutaneous sarcoid foreign body granulomas developing in sites of previous skin injury after systemic interferon-alpha treatment for chronic hepatitis C Br J Dermatol 140 1999 370 372
33. Kadayifcilar S Boyacioglu S Kart H Gursoy M Aydin P Ocular complications with high-dose interferon alpha in chronic active hepatitis Eye 13 1999 241 246
34. Krischer J Pechère M Salomon D Harms M Chavaz P Saurat JH Interferon alfa-2b-induced Myerson's nevi in a patient with dysplastic nevus syndrome J Am Acad Dermatol 40 1999 105 106
35. Hayasaka S Nagaki Y Matsumoto M Sato S Interferon associated retinopathy Br J Ophthalmol 82 1998 323 325
36. Lohmann CP Kroher G Bogenrieder T Spiegel D Preuner J Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma Lancet 353 1999 1326
37. Sugano S Suzuki T Watanabe M Ohe K Ishii K Okajima T Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C Am J Gastroenterol 93 1998 2441 2444
38. Cadoni G Marinelli L de Santis A Romito A Manna R Ottaviani F Sudden, hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis J Laryngol Otol 112 1998 962 963
39. Bell TM Bansal AS Shorthouse C Sandford N Powell EE Low-titre auto-antibodies predict autoimmune disease during interferon- α treatment of chronic hepatitis C Gastroenterol Hepatol 14 1999 419 422
40. Boonen A Stockbrügger RW Van der Linden S Pericarditis after therapy with interferon- α for chronic hepatitis C Clin Rheumatol 18 1999 177 179
41. Johnson DM Hayat SQ Burton GV Rheumatoid arthritis complicating adjuvant interferon- α therapy for malignant melanoma J Rheumatol 26 1999 1009 1010
42. Bren A Kandus A Ferluga D Rapidly progressive renal graft failure associated with interferon- α treatment in a patient, with chronic myelogenous leukemia Clin Nephrol 50 1998 266 267
43. Beelen DW Elmaagacli AH Schaefer UW The adverse influence of pretransplant interferon- α (IFN- α ) on transplant outcome after marrow transplantation for chronic phase chronic myelogenous leukemia increases with the duration of IFN- α exposure Blood 93 1999 1779 1780
44. Rostaing L Chatelut E Payen JL Izopet J Thalamas C Ton-That H Pascal JP Durand D Canal P Pharmacokinetics of α IFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications J Am Soc Nephrol 9 1998 2344 2348
45. Uchihara M Izumi N Sakai Y Yauchi T Miyake S Sakai T Akiba T Maumo F Sato C Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon Nephron 80 1998 51 56
46. Fiegl M Chott A Seewann HL Lechner K Gisslinger H Persisting bone marrow aplasia following interferon-alpha combined with Ara-C for chronic myelogenous leukemia Leuk Lymphoma 34 1999 191 195
47. Tappero G Ballaré M Farina M Negro F Severe anemia following combined α -interferon/ribavarin therapy of chronic hepatitis C J Hepatol 29 1998 1033 1034
48. Bramanti P Sessa E Rifici C D'Aleo C Floridia D Di Bella P Lublin F Enhanced spasticity in primary progressive MS patients treated with interfeeron beta-1b Neurology 51 1998 1720 1723
49. Borras C Rio J Porcel J Barrios M Tintoré M Montalban X Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b Neurology 52 1999 1636 1639
50. Rotondi M Oliviero A Profice P Mone CM Biondi B Del Buono A Mazziotti G Sinisi AM Bellastella A Carella C Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon- β therapy for multiple sclerosis J Endocrinol Invest 21 1998 748 752
51. Herrera WG Balizet LB Harberts SW Brown ST Occurrence of a TTP-like syndrome in two women receiving beta interferon therapy for relapsing multiple sclerosis Neurology 52 1999 135
52. Mehta CL Tyler RJ Cripps DJ Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon β -1b injections J Am Acad Dermatol 39 1998 1024 1028
53. Deisenhammer F Reindl M Harvey J Gasse T Dilitz E Berger T Biovailability of interferon beta 1b in MS patients with and without neutralizing antibodies Neurology 52 1999 1239 1243
54. Khan OA Dhib-Jalbut SS Neutralizing antibodies to interferon β -1a and interferon β 1b in MS patients are cross-reactive Neurology 51 1998 1698 1702
55. Rice GPA Paszner B Oger J Lesaux J Paty D Ebers G The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b Neurology 52 1999 1277 1279
56. Corona T Leon C Ostrosky-Zeichner L Severe anaphylaxis with recombinant interferon beta Neurology 52 1999 425
57. Clear D Anaphylactoid reaction to methyl prednisolone developing after starting treatment with interferon β-1b J Neurol Neurosurg Psychiatry 66 1999 690
58. Malaguarnera M Restuccia S Di Fazio I Di Marco R Pistone G Trovato BA Rapid evolution of chronic viral hepatitis into hepatocellular carcinoma after beta-interferon treatment Panminerva Med 41 1999 59 61
59. Furusyo N Hayashi J Ohmiya M Sawayama Y Kawakami Y Ariyama I Kinukawa N Kashiwagi S Differences between interferon-α and -β treatment for patients with chronic hepatitis C virus infection Dig Dis Sci 44 1999 608 617
60. Grassegger A Schuler G Hessenberger G Walder-Hantich B Jabrowski J Macheiner W Salmhofer W Zahel B Pinter G Herold M Klein G Fritsch PO Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial Br J Dermatol 139 1998 639 648
61. Carr A Emery S Lloyd A Hoy J Garsia R French M Stewart G Fyfe G Cooper DA Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study J Infect Dis 178 1998 992 999
62. Hengge UR Goos M Esser S Exner V Dötterer H Wiehler H Borchard C MĄller K Beckmann A Eppner MT Berger AM Fiedler M Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients AIDS 12 1998 F225 F234
63. Premkumar A Walworth CM Vogel S Daryanani KD Venzon DJ Kovacs JA Feuerstein IM Prospective sonographic evaluation of interleukin-2-induced changes in the gallbladder Radiology 206 1998 393 396
64. Hofstra LS Kristensen GB Willemse PHB Vindevoghel A Meden H Lahousen M Oberling F Sorbe B Crump M Sklenar I Sluiter WJ Kiese B Trope CG De Vries EGE Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during firstline chemotherapy for ovarian carcinoma J Clin Oncol 16 1998 3335 3344
65. Ballestrero A Ferrando F Garuti A Basta P Gonella R Stura P Mela GS Sessarego M Gobbi M Patrone F Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF J Clin Oncol 17 1999 1296 1303
66. Armitage JO Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor Blood 92 1998 4491 4508
67. Beveridge RA Miller JA Kales AN Binder RA Robert NJ Harvey JH Windsor K Gore I Cantrell J A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression Cancer Invest 16 1998 366 373
68. Fischmeister G Kurz M Haas OA Micksche M Buchinger P Printz D Ressmann G Stroebel T Peters C Fritsch G Gadner H G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability Ann Hematol 78 1999 117 123
69. Falanga A Marchetti M Evangelista V Manarini S Oldani E Giovanelli S Galbusera M Cerletti C Barbui T Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor Blood 93 1999 2506 2514
70. Falzetti F Aversa F Minelli O Tabilio A Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor Lancet 353 1999 555
71. Norol F Bonin P Charpentier F Bierling P Beaujean F Cartron JP Bories D Kuentz M Apparent reactivation of a red cell alloantibody in a healthy individual after G-CSF administration Br J Haematol 103 1998 256 258
72. Schaison G Eden OB Henze G Kamps WA Locatelli F Ninane J Ortega J Riikonen P Wagner HP Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel Eur J Pediatr 157 1998 955 966
73. Cairo MS Agosti J Ellis R Laver JJ Puppala B deLemos R Givner L Nesin M Wheeler JG Seth T Van De Ven C Fanaroff A A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates J Pediatr 134 1999 64 70
74. Beauchesne MF Shalansky SJ Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors Pharmacotherapy 19 1999 299 305
75. Vial T Gallant C Choquet-Kastylevsky G Descotes J Treatment of drug-induced agranulo-cytosis with haematopoietic growth factors. A review of the clinical experience BioDrugs 11 1999 185 200
76. Barbaro G Di Lorenzo G Grisorio B Soldini M Barbarini G Effect of recombinant human granulocyte-macrophage colony-stimulating factor, on HIV-related leukopenia: a randomized, controlled clinical study AIDS 11 1997 1453 1461
77. Couderc LJ Stelianides S Frachon I Stern M Epardeau B Baumelou E Caubarrere I Hermine O Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases Respir Med 93 1999 65 68
78. Ruiz-Argüelles G Arizpe-Bravo D Sanchez-Sosa S Rojas-Ortega S Moreno-Ford V Ruiz-Argüelles A Fatal G-CSF-induced pulmonary toxicity Am J Hematol 60 1999 82 83
79. Kasper C Jones L Fujita Y Morgenstern GR Scarffe JH Chang J Splenic rupture in a patient with acute myeloid leukemia undergoing peripheral blood stem cell transplantation Ann Hematol 78 1999 91 92
80. Yakisan E Schirg E Zeidler C Bishop NJ Reiter A Hirt A Riehm H Welte K High incidence of significant bone loss in patients with severe congenital neutropenia (Kostmann's syndrome) J Pediatr 131 1997 592 597
81. Dupre D Schoenlaub P Coloigner M Plantin P Réaction anaphylactique après injection locale de GM-CSF au cours d'un ulcère veineux de jambe Ann Dermatol Vénéréol 126 1999 160 161
82. Keung YK Suwanvecho S Cobos E Anaphylactoid reaction to granulocyte colony-stimulating factor used in mobilization of peripheral blood stem cell Bone Marrow Transplant 23 1999 200 201
83. Kaito K Kobayashi M Katayama T Masuoka H Shimada T Nishiwaki K Sekita T Otsubo H Ogasawara Y Hosoya T Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults Br J Haematol 103 1998 297 303
84. Nishimura M Yamada T Andoh T Tao T Emoto M Ohji T Matsuda K Kameda N Satoh Y Matsutani A Azuno Y Oka Y Granulocyte colony-stimulating factor (G-CSF) dependent hematopoiesis with monosomy 7 in a patient with severe aplastic anemia after ATG/CsA/G-CSF combined therapy Int J Hematol 68 1998 203 211
85. Shpall EJ Wheeler CA Turner SA Yanovich S Brown RA Pecora AL Shea TC Mangan KF Williams SF LeMaistre CF Long GD Jones R Davis MW Murphy-Filkins R Parker WRL Glaspy JA A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients Blood 8 1999 2491 2501
86. Charpentier B Thervet E Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation Transplant Proc 30 1998 1331 1332
87. Onrust SV Lamb HM Barman Balfour JA Rituximab Drugs 58 1999 79 88
88. Micallef INM Kirk A Norton A Foran JM Rohatiner AZS Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma Blood 93 1999 2427 2428
89. Tetreault S Abler SL Robbins B Saven A Peripheral T-cell lymphoma after anti-CD20 antibody therapy J Clin Oncol 16 1998 1635 1636
90. Sizmann N Korting HC Prolonged urticaria with 17-1A antibody Br Med J 317 1998 1631
91. Lundin J Osterborg A Brittinger G Crowther D Dombret H Engert A Epenetos A Gisselbrecht C Huhn D Jaeger U Thomas J Marcus R Nissen N Poynton C Rankin E Stahel R Uppenkamp M Willemze R Mellstedt H CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study J Clin Oncol 16 1998 3257 3263
92. Otton SH Turner DL Frewin R Davies SV Johnson SA Autoimmune thrombocytopenia after treatment with CAMPATH-1H in a patient with chronic lymphocytic leukaemia Br J Haematol 106 1999 252 262
93. Stolk JN Boerbooms AMT De Abreu RA De Koning DGM Van Beusekom HJ Muller WH Van De Putte LBA Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis Arthritis Rheum 41 1998 1858 1866
94. Black AJ McLeod HL Capell HA Powrie RH Matowe LK Pritchard SC Collie-Duguid ESR Reid DM Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine Ann Intern Med 129 1998 716 718
95. Amenabar JJ Gomez-Ullate P Garcia-Lopez FJ Aurrecoechea B Garcia-Erauzkin G Lampreabe I A randomized trial comparing cyclosporine and steroids with cyclosporine, azathioprine, and steroids in cadaveric renal transplantation Transplantation 65 1998 653 661
96. David-Neto E Da Fonseca JA De Paula FJ Nahas WC Sabbaga E Ianhez LE Is azathioprine harmful to chronic viral hepatitis in renal transplantation? A long-term study on azathioprine withdrawal Transplant Proc 31 1999 1149 1150
97. Azoulay D Castaing D Lemoine A Samuel D Majno P Reynes M Charpentier B Bismuth H Successful treatment of severe azathioprine-induced hepatic veno-occlusive disease in a kidney-transplanted patient with transjugular intrahepatic portosystemic shunt Clin Nephrol 50 1998 118 122
98. Stratton JD Farrington K Relapse of vasculitis, sepsis, or azathioprine allergy? Nephrol Dial Transplant 13 1998 2927 2928
99. Korelitz BI Fuller SR Warman JI Goldberg MD Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease Am J Gastroenterol 94 1999 424 426
100. Ippoliti G Negri M Campana C Vigano M Urate oxidase in hyperuricemic heart transplant recipients treated with azathioprine Transplantation 63 1997 1370 1371
101. Shah MB Martin JE Schroeder TJ First MR Validity of open labelled versus blinded trials: a meta-analysis comparing Neoral and Sandimmune Transplant Proc 31 1999 217 219
102. Taler SJ Textor SC Canzanello VJ Schwartz L Cyclosporin-induced hypertension. Incidence, pathogenesis and management Drug Saf 20 1999 437 449
103. Roelofs PM Klinkhamer PJ Gooszen HC Hypersensitivity pneumonitis probably caused by cyclosporine. A case report Resp Med 92 1998 1368 1370
104. Wijdicks EFM Dahlke LJ Wiesner RH Oral cyclosporine decreases severity of neuro-toxicity in liver transplant recipients Neurology 52 1999 1708 1710
105. Kotake S Higashi K Yoshikawa K Sasamoto Y Okamoto T Matsuda H Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy Ophthalmology 105 1999 586 589
106. Gopal AK Thorning DR Back AL Fatal outcome due to cyclosporine neurotoxicity with associated pathological findings Bone Marrow Transplant 23 1999 191 193
107. Kaito K Kobayashi M Ossubo H Ogasawara Y Sekita T Shimada T Hosoya T Cyclosporine and entrapment neuropathy. Report of two cases Acta Haematol 100 1998 159
108. Terrovitis IV Nanas SN Rombos AK Tolis G Nanas JN Reversible symmetric polyneuropathy with paraplegia after heart transplantation Transplantation 65 1998 1394 1413
109. Porges Y Blumen S Fireman Z Sternberg A Zamir D Cyclosporine-induced optic neuropathy, ophthalmoplegia, and nystagmus in a patient with Crohn disease Am J Ophthalmol 126 1998 607 609
110. Saito J Kami M Taniguchi F Kanda Y Takeda N Mitani K Hirai H Araie M Fujino Y Unilateral papilledema after bone marrow transplantation Bone Marrow Transplant 23 1999 963 965
111. Maghrabi K Bohlega S Cyclosporine-induced migraine with severe vomiting causing loss of renal graft Clin Neurol Neurosurg 100 1998 224 227
112. Cavdar C Sifil A Sanli E Gülay H Camsari T Hypomagnesemia and mild rhabdomyolysis in living related donor renal transplant recipient treated with cyclosporine A Scand J Urol Nephrol 32 1998 415 417
113. Parving HH Tarnow L Nielsen FS Rossing P Mandrup-Poulsen T Osterby R Nerup J Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study Diabetes Care 22 1999 478 483
114. Van der Molen L Van Son WJ Tegzess AM Stegeman CA Severe vital depression as the presenting feature of cyclosporin-A-associated thrombotic microangiopathy Nephrol Dial Transplant 14 1999 998 1000
115. Kohli HS Sud K Jha V Gupta KL Minz M Joshi K Sakhuja V Cyclosporin-induced haemolytic-uraemic syndrome presenting as primary graft dysfunction Nephrol Dial Transplant 13 1998 2940 2942
116. Lear J Bourke JF Burns DA Hyperplastic pseudofolliculitis barbae associated with cyclosporin Br J Dermatol 136 1997 132 148
117. De Felipe I Redondo P Eruptive angiomas after treatment with cyclosporine in a patient with psoriasis Arch Dermatol 134 1998 1487 1488
118. Mahendran R Grech C Generalized pustular psoriasis following a short course of cyclosporin (Neoral) Br J Dermatol 139 1998 934
119. Rebora A Delmonte S Parodi A Cyclosporin A-induced hair darkening Int Dermatol 38 1999 229 230
120. Liau-Chu M Theis JGW Koren G Mechanism of anaphylactoid reactions: improper preparation of high-dose intravenous cyclopsorine leads to bolus infusion of Cremophor EL and cyclospor Ann Pharmacother 31 1997 1287 1291
121. Hojo M Morimoto T Maluccio M Asano T Morimoto K Lagman M Shimbo T Suthanthiran M Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 1999 530 534
122. Jensen P Hansen S Moller B Leivestad T Pfeffer P Geiran O Fauchald P Simonsen S Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens J Am Acad Dermatol 40 1999 177 186
123. Brinkman K Huysmans F Burger DM Pharmacokinetic interaction between saquinavir and cyclosporine Ann Intern Med 129 1998 914 915
124. Park MH Pelegrin D Haug IMT Young JB Troglitazone, a new antidiabetic agent, decreases cyclosporine level J Heart Lung Transplant 17 1998 1139 1140
125. Tabbara KF Al-Faisal Z Al-Rashed W Interaction between acetazolamide and cyclosporine Arch Ophthalmol 116 1998 832 833
126. Tweddle DA Windebank KP Hewson QC Yule SM Cycloporin neurotoxicity after chemotherapy Br Med J 318 1999 1113
127. Haubitz M Schellong S Göbel U Schurek HJ Schaumann D Koch KM Brunkhorst R Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vascultis and renal involvement Arthritis Rheum 41 1998 1835 1844
128. Abuzarad H Gadallah MF Rabb H Vermess M Ramirez G Emphysematous cystitis: possible side-effect of cyclophosphamide therapy Clin Nephrol 50 1998 394 396
129. Garcia-Porrua C Gonzalez-Gay MA Pérez De Llano LA Alvarez-Ferreira JA Fatal interstitial pneumonia due to cytomegalovirus following cyclophosphamide treatment in a patient with systemic lupus erythematosus Scand J Rheumatol 27 1998 465 466
130. McCarthy CJ Sheldon S Ross CW McCune WJ Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease Arthritis Rheum 41 1998 1493 1496
131. Ortiz Z Shea B Suarez Almazor ME Moher D Wells GA Tugwell P The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials J Rheumatol 25 1998 36 43
132. Kokelj F Plozzer C Muzzi A Ciani F Endoalveolar haemorrhage due to methotrexate overdosage in a patient treated for psoriatic arthritis J Dermatol Treat 10 1999 67 69
133. Aplin CG Russell-Jones R Acute dysarthria induced by low dose methotrexate therapy in a patient with erythrodemic cutaneous T-cell lymphoma: an unusual manifestation of neurotoxicity Clin Exp Dermatol 24 1999 23 24
134. Malka N Reichert S Trechot P Barbaud A Schmutz JL Yellow nail pigmentation due to methotrexate Dermatology 197 1998 276
135. Georgescu L Paget SA Lymphoma in patients with rheumatoid arthritis. What is the evidence of a link with methotrexate? Drug Saf 20 1999 475 487
136. Hueso M Bover J Seron D Gil-Vernet S Sabate I Fulladosa X Ramos R Coll O Alsina J Grinyo JM Low-dose cyclospirne and mycophenolate mofetil in renal allograft recipients with suboptimal renal function Transplantation 66 1998 1727 1731
137. Stegall MD Wachs ME Everson G Steinberg T Bilir B Shrestha R Karrer F Kam I Prednisone withdrawal 14 days after liver transplantation with mycophenolate Transplantation 64 1997 1755 1760
138. Lecornu-Heuze L Ducloux D Rebibou JM martin L Billere C Chaplopin JM Mycophenolate mofetil in cyclosporin-associated thrombotic microangiopathy Nephrol Dial Transplant 13 1998 3212 3213
139. McGregor DO Robson RA Lynn KL Haemolytic-uraemic syndrome in a renal transplant recipient treated by conversion to mycophenolate mofetil Nephron 80 1998 365 366
140. Simmons WD Rayhill SC Sollinger HW Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection Drug Saf 17 1997 75 92
141. Odorico JS Pirsch JD Knechtle SJ D'Alessandro AM Sollinger HW A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation Transplantation 66 1998 1751 1759
142. Gruessner RWG Sutherland DER Drangsteivt MB Wrenshall L Humar A Gruessner AC Mycophenolate mofetil in pancreas transplantation Transplantation 66 1998 318 323
143. Shapiro R Jordan ML Scantlebury VP Vivas C Gritsch HA Casavilla FA McCauley J Johnston JR Randhawa P Irish W Hakal TR Fung JJ Starzl TE A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report J Urol 160 1998 1982 1986
144. Ducloux D Ottignon Y Semhoun-Ducloux S Labbé S Saint-Hillier Y Miguet JP Carayon P Chalopin JM Mycophenolate mofetil-induced villous atrophy Transplantation 66 1998 1115 1116
145. Daoud AJ Schroeder TJ Shah M Hariharan S Peddi VR Weiskittel P First MR A comparison of the safety and efficacy of mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, and prednisone and tacrolimus Transplant Proc 30 1998 4079 4081
146. Gomez E Aguado S Rodriguez M Alvarez-Grande J Kaposi's sarcoma after renal transplantation—disappearance after reduction of immunosuppression and reappearance 7 years after start of mycophenolate mofetil treatment Nephrol Dial Transplant 13 1998 3279 3280
147. Kahan BD Podbielski J Napoli KL Katz SM Meier-Kriesche HU Van Buren CT Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation Transplantation 66 1998 1040 1046
148. Kaplan MJ Ellis CN Bata-Csorgo Z Kaplan RS Endres JL Fox DA Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis. Association of capillary leak syndrome with apoptosis of lesional lymphocytes Arch Dermatol 135 1999 553 557
149. Jain AB Kashyap R Rakela J Starzl TE Fung JJ Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events Liver Transplant Surg 5 1999 144 150
150. Kliem V Brunkhorst R Tacrolimus in kidney transplantation. A clinical review Nephron 79 1998 8 20
151. Chang RKR Alzona M Alejos J Jue K McDiarmid SV Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation Am J Cardiol 81 1998 1277 1280
152. Scott JS Boyle GJ Daubeney PF Miller SA Law Y Pigula F Griffith BP Webber SA Tacrolimus: a cause of hypertrophic cardiomyopathy in pediatric heart transplant recipients? Transplant Proc 31 1999 82 83
153. Canzanello VJ Textor SC Taler SJ Schwartz LL Porayko MK Wiesner RH Krom RAF Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK506) Liver Transplant Surg 4 1998 328 334
154. Taylor DO Barr ML Radovancevic B Renlund DG Mentzer RM Smart FW Tolman DE Frazier OH Young JB Van Veldhuisen P A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus J Heart Lung Transplant 18 1999 336 345
155. Steg RE Kessinger A Wszolek ZK Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation Bone Marrow Transplant 23 1999 959 962
156. Tomura N Kurosawa R Kato K Takahashi S Watarai J Takeda O Watanabe A Takada G Transient neurtoxicity associated with FK506: MR findings J Comput Assisted Tomogr 22 1998 505 507
157. Torocsik HV Curless RG Post J Tzakis AG Pearse L FK506-induced leukoencephalopathy in children with organ transplants Neurology 52 1999 1497 1500
158. Knoll GA Bell RC Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials Br Med J 318 1999 1104 1107
159. Cavaillé-Coll MW Elashoff MR Commentary on a comparison of tacrolimus and cyclosporine for immunsuppression after cadaveric renal transplantation Transplantation 65 1998 142 145
160. Yoshioka K Sato T Okada N Ishii T Imanishi M Tanaka S Kim T Sugimoto T Fujii S Post-transplant diabetes with anti-glutamic acid decarboxylase antibody during tacrolimus therapy Diabetes Res Clin Pract 42 1998 85 89
161. Sharma AK Holder FE Clostridium difficile diarrhea after use of tacrolimus following renal transplantation Clin Infect Dis 27 1998 1540 1541
162. Solez K Vincenti F Filo RS Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine. A report of the FK506 kidney transplant study group Transplantation 66 1998 1736 1740
163. Walder B Ricou B Suter PM Tacrolimus (FK 506)-induced hemolytic uremic syndrome after heart transplantation J Heart Lung Transplant 17 1998 1004 1006
164. Trimarchi HM Truong LD Brennan S Gonzalez JM Suki WN FK506-associated thrombotic microangiopathy Transplantation 67 1999 539 544
165. Schmidt RH Lenz T Gröne HJ Geiger H Scheuermann EH Haemolytic-uraemic syndrome after tacrolimus rescue therapy for cortisone-resistant rejection Nephrol Dial Transplant 14 1999 979 983
166. Basile C Marangi AL Montanaro A Giordano R De Padova F Ligorio VA Santese D Di Marco L Semeraro A Vernaglione L Tacrolimus and gingival hyperplasia Nephrol Dial Transplant 13 1998 2980 2981
167. Vyas S Kumar A Piecuch S Hidalgo G Singh A Anderson V Markell MS Baqi N Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus Transplantation 67 1999 490 492
168. Odoul F Talbotec C Boussa N Le Guellec C Furet Y Maurage C Breteau M Massive ingestion of tacrolimus in a young liver transplant patient Transplant Proc 30 1998 4327 4329
169. Campo JV Smith C Perel JM Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent Arch Gen Psychiatry 55 1998 1050 1052
170. Krähenbühl S Menafoglio A Giostra E Gallino A Serious interaction between mibefradil and tacrolimus Transplantation 66 1998 1113 1115
171. Herzig K Johnson DW Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy Nephrol Dial Transplant 14 1999 521 523
172. Hanagiri T Muranaka H Hashimoto M Nagashima A A syndrome of inappropriate secretion of antidiuretic hormone associated with pleutitis caused by OK-432 Respiration 65 1998 310 312